INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒══════════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                    │   Score │
╞══════════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Patient currently has no evidence of progressive │ Patient currently has no evidence of progressive │      85 │
│ disease, as determined by the investigator,      │ disease, as determined by the investigator,      │         │
│ following previous treatment with ruxolitinib or │ following previous treatment with ruxolitinib    │         │
│ combination of ruxolitinib and panobinostat      │                                                  │         │
╘══════════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 1 Month                   │ Patient is currently benefiting from the treatment │      27 │
│                                                    │ with ruxolitinib, as determined by the             │         │
│                                                    │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing (lactating) women              │ Patient is currently benefiting from the treatment │      32 │
│                                                    │ with ruxolitinib, as determined by the             │         │
│                                                    │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other protocol-defined Inclusion / Exclusion       │ Patient is currently benefiting from the treatment │      34 │
│ criteria may apply                                 │ with ruxolitinib, as determined by the             │         │
│                                                    │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Key                                                │ Patient is currently benefiting from the treatment │       4 │
│                                                    │ with ruxolitinib, as determined by the             │         │
│                                                    │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient's indication is currently approved and     │ Patient is currently benefiting from the treatment │      51 │
│ reimbursed in the corresponding country for        │ with ruxolitinib, as determined by the             │         │
│ ruxolitinib monotherapy or combination of          │ investigator                                       │         │
│ ruxolitinib and panobinostat                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has been permanently discontinued from     │ Patient is currently benefiting from the treatment │      56 │
│ study treatment in the parent study due to any     │ with ruxolitinib, as determined by the             │         │
│ reason                                             │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female patients of childbearing potential (e.g.    │ Women of child-bearing potential, defined as all   │      57 │
│ are menstruating) who do not agree to abstinence   │ women physiologically capable of becoming          │         │
│ or, if sexually active, do not agree to the use of │ pregnant, unless they are using highly effective   │         │
│ highly effective contraception, throughout the     │ methods of contraception throughout the study      │         │
│ study and for up to 30 days after stopping study   │ duration inclusive of the 30-day safety follow up  │         │
│ treatment                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has demonstrated compliance, as assessed   │ Patient has demonstrated compliance, as assessed   │      68 │
│ by the investigator, with the parent study         │ by the investigator, with the parent study         │         │
│ protocol requirements                              │ protocol requirements Willingness and ability to   │         │
│                                                    │ comply with scheduled visits, treatment plans and  │         │
│                                                    │ any other study procedures                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently enrolled in a Novartis GDD or │ Patient is currently enrolled in a Novartis OGD or │      72 │
│ GMA-sponsored or Incyte-sponsored clinical study,  │ GMA-sponsored or Incyte-sponsored clinical study   │         │
│ are receiving either ruxolitinib or combination of │ (where Incyte can delegate the sponsorship to a    │         │
│ ruxolitinib and panobinostat, and fulfilled all of │ preferred CRO, if applicable) that is approved to  │         │
│ the requirements of the parent protocol            │ enroll into this rollover study, is receiving      │         │
│                                                    │ ruxolitinib and has fulfilled all of the           │         │
│                                                    │ requirements of the parent protocol                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently benefiting from the treatment │ Patient is currently benefiting from the treatment │      78 │
│ with ruxolitinib monotherapy or combination of     │ with ruxolitinib, as determined by the             │         │
│ ruxolitinib and panobinostat, as determined by the │ investigator                                       │         │
│ investigator                                       │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patient is currently enrolled in a Novartis GDD or │ Written informed consent obtained prior to         │      44 │
│ GMA-sponsored or Incyte-sponsored clinical study,  │ enrolling in roll-over study and receiving study   │         │
│ are receiving either ruxolitinib or combination of │ medication. If consent cannot be expressed in      │         │
│ ruxolitinib and panobinostat, and fulfilled all of │ writing, it must be formally documented and        │         │
│ the requirements of the parent protocol            │ witnessed, ideally via an independent trusted      │         │
│                                                    │ witness                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently benefiting from the treatment │ Pregnant or nursing (lactating) women, where       │      45 │
│ with ruxolitinib monotherapy or combination of     │ pregnancy is defined as the state of a female      │         │
│ ruxolitinib and panobinostat, as determined by the │ after conception and until the termination of      │         │
│ investigator                                       │ gestation, confirmed by a positive hCG laboratory  │         │
│                                                    │ test                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently benefiting from the treatment │ Patient has participated in a combination trial    │      52 │
│ with ruxolitinib monotherapy or combination of     │ where ruxolitinib was dispensed in combination     │         │
│ ruxolitinib and panobinostat, as determined by the │ with another study medication and the patient is   │         │
│ investigator                                       │ still receiving combination therapy                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female patients of childbearing potential (e.g.    │ Women of child-bearing potential, defined as all   │      57 │
│ are menstruating) who do not agree to abstinence   │ women physiologically capable of becoming          │         │
│ or, if sexually active, do not agree to the use of │ pregnant, unless they are using highly effective   │         │
│ highly effective contraception, throughout the     │ methods of contraception throughout the study      │         │
│ study and for up to 30 days after stopping study   │ duration inclusive of the 30-day safety follow up  │         │
│ treatment                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has demonstrated compliance, as assessed   │ Patient has demonstrated compliance, as assessed   │      68 │
│ by the investigator, with the parent study         │ by the investigator, with the parent study         │         │
│ protocol requirements                              │ protocol requirements Willingness and ability to   │         │
│                                                    │ comply with scheduled visits, treatment plans and  │         │
│                                                    │ any other study procedures                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently enrolled in a Novartis GDD or │ Patient is currently enrolled in a Novartis OGD or │      72 │
│ GMA-sponsored or Incyte-sponsored clinical study,  │ GMA-sponsored or Incyte-sponsored clinical study   │         │
│ are receiving either ruxolitinib or combination of │ (where Incyte can delegate the sponsorship to a    │         │
│ ruxolitinib and panobinostat, and fulfilled all of │ preferred CRO, if applicable) that is approved to  │         │
│ the requirements of the parent protocol            │ enroll into this rollover study, is receiving      │         │
│                                                    │ ruxolitinib and has fulfilled all of the           │         │
│                                                    │ requirements of the parent protocol                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently benefiting from the treatment │ Patient is currently benefiting from the treatment │      78 │
│ with ruxolitinib monotherapy or combination of     │ with ruxolitinib, as determined by the             │         │
│ ruxolitinib and panobinostat, as determined by the │ investigator                                       │         │
│ investigator                                       │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 63
Average Levenshtein Ratio of individual lines: 54.44444444444444
OverAll Ratio: 58.72222222222222
